靶向治疗：舒尼替尼与干扰素-α治疗转移性肾细胞癌。
Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC.
机构信息
Massachusetts General Hospital Cancer Center, The Claire and John Bertucci Center for Genitourinary Cancers, 55 Fruit Street, Boston, MA 02114, USA.
出版信息
Nat Rev Clin Oncol. 2010 Jan;7(1):7-8. doi: 10.1038/nrclinonc.2009.173.
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
莫泽特及其同事报告了舒尼替尼对比干扰素-α一线治疗转移性肾细胞癌患者的多中心 III 期临床试验的更新结果。舒尼替尼治疗患者的总生存改善进一步确立了该药物作为转移性肾肿瘤低危和中危患者一线治疗的参考标准。
Zotero 插件